Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ESMO 2018

19 - 23 Oct 2018

Messe Munich, Munich, Germany

ESMO 2018: Immunotherapy improves survival in metastatic or recurrent head and neck cancer

ESMO 2018: Immunotherapy improves survival in metastatic or recurrent head and neck cancer

ESMO 2018: Patients with HPV-positive oropharynx cancer should receive chemoradiation

ESMO 2018: Patients with HPV-positive oropharynx cancer should receive chemoradiation

ESMO 2018: Major response to immunotherapy in early stage mismatch repair deficient colon cancer

ESMO 2018: Major response to immunotherapy in early stage mismatch repair deficient colon cancer

ESMO 2018: Immunotherapy may become new first line treatment in some metastatic colorectal cancers

ESMO 2018: Immunotherapy may become new first line treatment in some metastatic colorectal cancers

ESMO 2018: Multi-strain probiotic reduces chemotherapy-induced diarrhoea

ESMO 2018: Multi-strain probiotic reduces chemotherapy-induced diarrhoea

ESMO 2018: Barriers to early clinical trial access for adolescents and young adults still exist, study shows

ESMO 2018: Barriers to early clinical trial access for adolescents and young adults still exist, study shows

ESMO 2018: Avelumab plus axitinib significantly improve PFS in untreated renal cell carcinoma

ESMO 2018: Avelumab plus axitinib significantly improve PFS in untreated renal cell carcinoma

ESMO 2018: Local radiotherapy improves survival in metastatic prostate cancer with low disease burden

ESMO 2018: Local radiotherapy improves survival in metastatic prostate cancer with low disease burden

ESMO 2018: Drugs for treating breast cancer in women are effective and well tolerated in men

ESMO 2018: Drugs for treating breast cancer in women are effective and well tolerated in men

ESMO 2018: Olaparib maintenance extends PFS by estimated 3 years in advanced ovarian cancer

ESMO 2018: Olaparib maintenance extends PFS by estimated 3 years in advanced ovarian cancer

ESMO 2018: Erlotinib improves progression-free survival in early mutated non-small cell lung cancer

ESMO 2018: Erlotinib improves progression-free survival in early mutated non-small cell lung cancer

ESMO 2018: Zoledronic acid improves disease-free survival in premenopausal HR early breast cancer

ESMO 2018: Zoledronic acid improves disease-free survival in premenopausal HR early breast cancer

ESMO 2018: Targeting specific genomic mutation in breast cancer improves outcomes, first study shows

ESMO 2018: Targeting specific genomic mutation in breast cancer improves outcomes, first study shows

ESMO 2018: Some patients with metastatic triple negative breast cancer live longer with immunotherapy

ESMO 2018: Some patients with metastatic triple negative breast cancer live longer with immunotherapy

ESMO 2018: New option for women with advanced breast cancer resistant to hormone therapy

ESMO 2018: New option for women with advanced breast cancer resistant to hormone therapy

ESMO 2018: Epigenetic therapy worth pursuing in hormone receptor positive advanced breast cancer

ESMO 2018: Epigenetic therapy worth pursuing in hormone receptor positive advanced breast cancer

ESMO 2018: One in six premenopausal early breast cancer patients do not adhere to hormonal therapy

ESMO 2018: One in six premenopausal early breast cancer patients do not adhere to hormonal therapy

ESMO 2018: Shorter-course trastuzumab could be an option in HER2 positive early breast cancers

ESMO 2018: Shorter-course trastuzumab could be an option in HER2 positive early breast cancers

ESMO 2018: Huge variations between countries in time for reimbursement decisions on new cancer drugs

ESMO 2018: Huge variations between countries in time for reimbursement decisions on new cancer drugs

ESMO 2018: AACR CEO Margaret Foti Honored with Women for Oncology Award from ESMO

ESMO 2018: AACR CEO Margaret Foti Honored with Women for Oncology Award from ESMO

ESMO 2018: Oncologists demand more education on the use of biosimilars

ESMO 2018: Oncologists demand more education on the use of biosimilars

ESMO 2018: Women more prone to selected oesophagogastric cancer chemotherapy side-effects

ESMO 2018: Women more prone to selected oesophagogastric cancer chemotherapy side-effects

ESMO 2018: Financial impacts of cancer found to intensify disease burden among German patients

ESMO 2018: Financial impacts of cancer found to intensify disease burden among German patients

ESMO 2018: ESMO advocacy for patient-centred care takes on global dimension

ESMO 2018: ESMO advocacy for patient-centred care takes on global dimension

More from ecancer